Patent intelligence · US
US 6331564
Use of triaryl methane compounds for inhibiting unwanted cellular proliferation associated with inflammatory disease
Use of triaryl methane compounds for inhibiting unwanted cellular proliferation associated with inflammatory disease
Patent details — US 6331564
- Jurisdiction
- US
- Status
- expired
- Grant date
- Dec 18, 2001
- Expiration
- Dec 13, 2021
- Applicant
- Ion Pharmaceuticals, Inc.
- Claims
- 13
- CPC classes
- A61K, A61K31/03, A61K31/05, A61K31/075
Quick answer
US 6331564 (Use of triaryl methane compounds for inhibiting unwanted cellular proliferation associated with inflammatory disease) is held by Ion Pharmaceuticals, Inc.. Status: expired. Granted Dec 18, 2001. Expires Dec 13, 2021 (0 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Ion Pharmaceuticals, Inc.
- Grant date
- Expiration
- Claims
- 13
- CPC classes
- A61K, A61K31/03, A61K31/05, A61K31/075, A61K31/085, A61K31/10
More from Ion Pharmaceuticals, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 11919868
Heterocyclic compounds and related methods
granted -
US 11033494
Apparatuses containing an emulsion and methods of manufacture
granted -
US 6028103
Triaryl methane compounds and analogues thereof useful for the treatment or prevention of sickle cell disease or diseases characterized by abnormal cell proliferation
expired
Frequently asked questions
What is US patent 6331564?
US 6331564 (Use of triaryl methane compounds for inhibiting unwanted cellular proliferation associated with inflammatory disease) is held by Ion Pharmaceuticals, Inc.. Status: expired. Granted Dec 18, 2001. Expires Dec 13, 2021 (0 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 6331564?
Ion Pharmaceuticals, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 4 pharmaceutical patents for this assignee.
When does US 6331564 expire?
Our index shows an expiration date of Dec 13, 2021 (0 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.